EyePoint Pharmaceuticals, Inc.
EYPT
$14.52
$0.836.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -7.38% | 2.99% | 12.04% | -5.97% | 7.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.38% | 2.99% | 12.04% | -5.97% | 7.50% |
| Cost of Revenue | 86.45% | 88.92% | 90.70% | 95.62% | 57.58% |
| Gross Profit | -153.92% | -179.41% | -203.91% | -304.30% | -136.94% |
| SG&A Expenses | 6.58% | 9.02% | 7.05% | 4.97% | -2.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.23% | 61.70% | 58.87% | 56.19% | 30.91% |
| Operating Income | -86.65% | -91.70% | -85.84% | -94.30% | -43.08% |
| Income Before Tax | -98.64% | -101.99% | -86.08% | -84.95% | -3.33% |
| Income Tax Expenses | 120.48% | 120.48% | 8.43% | 8.43% | -- |
| Earnings from Continuing Operations | -98.66% | -102.00% | -86.00% | -84.86% | -3.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -98.66% | -102.00% | -86.00% | -84.86% | -3.42% |
| EBIT | -86.65% | -91.70% | -85.84% | -94.30% | -43.08% |
| EBITDA | -86.77% | -91.49% | -85.25% | -93.44% | -42.83% |
| EPS Basic | -49.03% | -49.11% | -31.81% | -25.87% | 24.76% |
| Normalized Basic EPS | -49.05% | -49.12% | -34.52% | -28.44% | 3.49% |
| EPS Diluted | -49.03% | -49.11% | -31.81% | -25.87% | 24.76% |
| Normalized Diluted EPS | -49.05% | -49.12% | -34.52% | -28.44% | 3.49% |
| Average Basic Shares Outstanding | 35.36% | 38.62% | 41.51% | 44.71% | 34.48% |
| Average Diluted Shares Outstanding | 35.36% | 38.62% | 41.51% | 44.71% | 34.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |